Oxford Biomedica (LON: OXB) net income
Oxford Biomedica reported a net loss of £30.1m for fiscal 2025; in fiscal 2024 it reported a net loss of £43.2m. Earnings per share were −£0.27.
Oxford Biomedica's best year of the last 5 was fiscal 2021. It reported a loss in 4 of those 5 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −£30.1m | — | −17.9% | −£0.27 |
| 2024 | −£43.2m | — | −33.5% | −£0.42 |
| 2023 | −£157.5m | — | −175.9% | −£1.63 |
| 2022 | −£39.2m | −306.0% | −28.0% | −£0.41 |
| 2021 | £19.0m | — | 13.3% | £0.23 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of pounds, except per-share amounts.
Oxford Biomedica net income compared with its sector
By net income for its latest fiscal year, Oxford Biomedica ranks 52nd of the 65 Spanish and European health care companies with a page on Celsmar. The sector median net margin is 5.8%; that of Oxford Biomedica, −17.9%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 50th | Carvolix | −€25.0m | — |
| 51st | MedinCell | −€31.3m | −128.9% |
| 52nd | Oxford Biomedica | −£30.1m | −17.9% |
| 53rd | Transgene | −€37.5m | −27,389.8% |
| 54th | OSE Immunotherapeutics | −€37.7m | −1,439.1% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in health care stocks.
Questions about the net income of Oxford Biomedica
- How much did Oxford Biomedica earn in fiscal 2025?
- Oxford Biomedica reported a net loss of £30.1m for fiscal 2025. In fiscal 2024 it reported a net loss of £43.2m.
- What are the earnings per share of Oxford Biomedica?
- They were −£0.27 in fiscal 2025, compared with −£0.42 in fiscal 2024.
- What was the most profitable year for Oxford Biomedica?
- Of its last 5 fiscal years, fiscal 2021, with £19.0m.
- Where does Oxford Biomedica rank in its sector by net income?
- It ranks 52nd of the 65 Spanish and European health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Oxford Biomedica come from?
- From the report Oxford Biomedica files every year in the European single electronic format (ESEF), the one it files with the regulator of its home market. Each fiscal year links to its filing.
Where each figure comes from
From the annual report Oxford Biomedica files every year in the European single electronic format (ESEF). The filing for each fiscal year: 2025 · 2024 · 2023 · 2022. More on Oxford Biomedica: the Oxford Biomedica page · annual accounts · revenue.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.